Why the study?
Does an early decline in left ventricular ejection fraction predict later doxorubicin cardiotoxicity in adult patients with non-Hodgkin's lymphoma?
Population
30 adult patients with non-Hodgkin's lymphoma (28 evaluable who received doxorubicin ≥400 mg/m²)
Design
Cohort
Follow-up
Until cumulative doxorubicin dose of 500 mg/m²
Authors
Loading...
Early LVEF decline after low-dose doxorubicin may flag high-risk lymphoma patients for monitoring; hypothesis-generating pending prospective validation.
Does an early decline in left ventricular ejection fraction predict later doxorubicin cardiotoxicity in adult patients with non-Hodgkin's lymphoma?
An early decline in left ventricular ejection fraction at a low cumulative doxorubicin dose (200 mg/m²) is a strong predictor of subsequent anthracycline-induced cardiotoxicity.
Nousiainen et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: